Today, a Director at Nektar Therapeutics (NASDAQ: NKTR), Dennis Winger, sold shares of NKTR for $2.08M.
Following Dennis Winger’s last NKTR Sell transaction on January 08, 2018, the stock climbed by 1.2%.
See today’s analyst top recommended stocks >>
Based on Nektar Therapeutics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $1.09 billion and quarterly net profit of $971 million. In comparison, last year the company earned revenue of $34.59 million and had a GAAP net loss of $59.87 million. NKTR’s market cap is $10.41B and the company has a P/E ratio of 11.99. Currently, Nektar Therapeutics has an average volume of 1.89M.
Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $90.00, reflecting a -34.9% downside.
The insider sentiment on Nektar Therapeutics has been positive according to 82 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. It operates through the United States and Europe geogrpahical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
